Ketamine for Chronic Pain: Evidence Review Finds No Support

Ketamine for Chronic Pain: A Lack of Evidence

A complete Cochrane review reveals a lack of scientific support for the off-label use of ⁤ketamine – and other NMDA receptor antagonists like memantine, dextromethorphan, amantadine, and magnesium – in treating ⁤chronic pain conditions. The review, encompassing 67 trials and over 2,300 participants, found ⁢no clear evidence of benefit across conditions like nerve pain, fibromyalgia, and complex regional⁤ pain syndrome.

Researchers identified a concerning trend: increased risk of adverse effects associated with ketamine use, including ⁣delusions, delirium, paranoia, nausea, and vomiting. The certainty of the evidence was rated as low to very low, largely due to limitations in study design and⁢ size.

Key Findings & Concerns

• No Consistent Benefit: No clear evidence of pain reduction was found across various chronic pain conditions or dosage strategies.
• significant Side Effects: Psychotomimetic effects (delusions, delirium, paranoia) and gastrointestinal issues were commonly reported.
• Uncertain ⁤Impact on Co-morbidities: The review did not provide data on ketamine’s effect on depressive symptoms or opioid use – areas where it is often considered ⁤as⁢ a potential treatment.

Experts ⁢emphasize the need for caution,⁣ noting a⁤ pattern of⁣ applying acute pain medications to chronic pain without sufficient evidence, as ⁣seen with opioids. The review underscores the ⁤urgent need for rigorous, high-quality clinical trials to determine if ketamine has a legitimate role in chronic pain ⁢management. Clinicians ⁢and patients should carefully weigh potential risks and benefits,‍ recognizing the current lack of conclusive evidence supporting its use.

This research highlights the importance⁣ of⁣ evidence-based medicine and the potential harms of widespread adoption of treatments without robust scientific validation.